This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-25 and is reviewed periodically as new material appears.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
== Scientific implications and other uses == SPINA-Beta significantly correlates with biomarkers for the allostatic load. The direction is positive, i. e., higher allostatic load is associated with higher beta cell function. This is probably due to increased beta cell mass as a result of dynamical compensation. Together with the reconstructed insulin receptor gain (SPINA-GR), SPINA-GBeta provides the foundation for the definition of a fasting based disposition index of insulin-glucose homeostasis (SPINA-DI). In combination with SPINA-GR and whole-exome sequencing, calculating SPINA-GBeta helped to identify a new form of monogenetic diabetes (MODY) that is characterised by primary insulin resistance and results from a missense variant of the type 2 ryanodine receptor (RyR2) gene (p.N2291D).
While the 30-day stunt was not an officially endorsed marketing campaign by Taco Bell, then CEO Mark King later invited Reid to Taco Bell's headquarters in Irvine, California. Reid was also a guest on an official Taco Bell podcast in 2023, discussing the stunt and its effect on his physical health. In 2023, the company test-marketed a vegan Crunchwrap Supreme in Los Angeles, New York, and Orlando to gauge the potential of a national roll out. Bon Appétit tested a vegan Crunchwrap alongside a non-vegan Crunchwrap purchased at the store in midtown Manhattan and said "the differences between the two were also genuinely difficult to discern." On August 29, 2025, the company announced that it would be abrogating its artificial intelligence-powered drive-thrus due to technical difficulties and "trolling," including one instance where a customer ordered 18,000 waters. According to reports, the AI would erroneously tell customers that the store was out of all ingredients except for soda and sauce packets. There were also reports of the AI bots simply disallowing customers to modify their orders, such as replacing meat with beans. The phenomenon quickly became an internet meme. One video on TikTok appeared to show a customer attempting to order McDonald's food items from Taco Bell, which was allowed by the system. Dane Mathews, the chain's Chief Digital and Technology Officer, told the Wall Street Journal: "We’re learning a lot, I’m going to be honest with you. [...] I can tell you it's a very active conversation inside Taco Bell in partnership with our franchisees.
=== Material Science Applications === Organic Electronics Polymeric Materials Consumer Packaged Goods Catalysis & Reactivity Thin Film Processing Energy Capture & Storage Pharmaceutical Formulations & Delivery Metals, Alloys & Ceramics In addition to computational platforms, Schrödinger develops custom software for enterprises, as well as training, computer-cluster design and implementation, and research-based drug discovery projects. Schrödinger software licenses are available to academic institutions for education and not-for-profit research.
Alexander Fleming discovered the world's first antibiotic, penicillin, which Florey and Chain then developed. Gerhard Domagk developed sulphonamides, the first broad spectrum synthetic antibacterial drugs.
=== The American Revolution === After his disenchantment with socialism, Hitchens increasingly emphasized the centrality of the American Revolution and the U.S. Constitution to his political philosophy. As early as 2002, Hitchens wrote, "as the third millennium gets under way, and as the Russian and Chinese and Cuban revolutions drop below the horizon, it is possible to argue that the American revolution, with its promise of cosmopolitan democracy, is the only 'model' revolution that humanity has left to it". His enthusiasm for the U.S. Bill of Rights contrasts with a dim opinion of constitutional politics on the other side of the Atlantic. Hitchens notes, "the utter failure [of the EU] to compose a viable constitution" and the "brevity of the British constitution, perhaps because the motherland of the English-speaking peoples has absent-mindedly failed to evolve one in written form".
Sources: en.wikipedia.org
GlcA = β-D-glucuronic acid, IdoA = α-L-iduronic acid, IdoA(2S) = 2-O-sulfo-α-L-iduronic acid, GlcNAc = 2-deoxy-2-acetamido-α-D-glucopyranosyl, GlcNS = 2-deoxy-2-sulfamido-α-D-glucopyranosyl, GlcNS(6S) = 2-deoxy-2-sulfamido-α-D-glucopyranosyl-6-O-sulfate One unit of heparin (the "Howell unit") is an amount approximately equivalent to 0.002 mg of pure heparin, which is the quantity required to keep 1 ml of cat's blood fluid for 24 hours at 0 °C.
== Use == A common way to synthesize an NHS-activated acid is to mix NHS with the desired carboxylic acid and a small amount of an organic base in an anhydrous solvent. A coupling reagent such as dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is then added to form a highly reactive activated acid intermediate. NHS reacts to create a less labile activated acid. The group is usually written as SuO- or -OSu in chemical notation. Such an ester with acid and NHS, sometimes called succinate ester, is stable enough to be purified and stored at low temperatures in the absence of water and, as such, is commercially available. NHS esters are commonly used for protein modification (e.g. an NHS ester of fluorescein is commercially available, and can be added to a protein to obtain a fluorescently labeled protein in a straightforward reaction and purification step). NHS can be used with EDC to immobilize enzymes for biosensor applications.
In the industrialized world, the United States is the world's biggest consumer of prescription opioids, with Italy being one of the lowest, because of tighter regulations on prescribing narcotics for pain relief. Most opium imported into the United States is broken down into its alkaloid constituents, and whether legal or illegal, most current drug use occurs with processed derivatives such as heroin rather than with unrefined opium. Intravenous injection of opiates is most used: by comparison with injection, "dragon chasing" (heating of heroin on a piece of foil), and madak and "ack ack" (smoking of cigarettes containing tobacco mixed with heroin powder) are only 40 percent and 20 percent efficient, respectively. One study of British heroin addicts found a 12-fold excess mortality ratio (1.8 percent of the group dying per year). Most heroin deaths result not from overdose per se, but combination with other depressant drugs such as alcohol or benzodiazepines. The smoking of opium does not involve the burning of the material as might be imagined. Rather, the prepared opium is indirectly heated to temperatures at which the active alkaloids, chiefly morphine, are vaporized. In the past, smokers would use a specially designed opium pipe which had a removable knob-like pipe-bowl of fired earthenware attached by a metal fitting to a long, cylindrical stem.
== History == The US Food and Drug Administration (FDA) approved trastuzumab deruxtecan based on the results of one clinical trial enrolling 184 female participants with HER2-positive, unresectable and/or metastatic breast cancer who had received two or more prior anti-HER2 therapies in the metastatic setting. These participants were heavily pretreated in the metastatic setting, receiving between two and 17 therapies prior to receiving trastuzumab deruxtecan. Participants in the clinical trial received trastuzumab deruxtecan every three weeks and tumor imaging was obtained every six weeks. The overall response rate was 60.3%, which reflects the percentage of participants who had a certain amount of tumor shrinkage with a median duration of response of 14.8 months. Efficacy was evaluated in a multicenter, open-label, randomized trial (DESTINY-Gastric01, NCT03329690) in participants with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least two prior regimens, including trastuzumab, a fluoropyrimidine- and a platinum-containing chemotherapy. A total of 188 participants were randomized (2:1) to receive trastuzumab deruxtecan 6.4 mg/kg intravenously every three weeks or physician's choice of either irinotecan or paclitaxel monotherapy.
Each exists in the form of a hydrogen phosphate anion ([HPO4]2−), dissociating to contribute 2H+ overall Each liberates an oxygen atom when it binds to an adenosine diphosphate (ADP) molecule, contributing 2 O overall Charges are balanced by the difference between ADP and ATP. In the cellular environment, all three hydroxyl groups of ADP dissociate into −O− and H+, giving ADP3−, and this ion tends to exist in an ionic bond with Mg2+, giving ADPMg−. ATP behaves identically except that it has four hydroxyl groups, giving ATPMg3−. When these differences along with the true charges on the two phosphate groups are considered together, the net charges of −4 on each side are balanced. In high-oxygen (aerobic) conditions, eukaryotic cells can continue from glycolysis to metabolise the pyruvate through the citric acid cycle or the electron transport chain to produce significantly more ATP. Importantly, under low-oxygen (anaerobic) conditions, glycolysis is the only biochemical pathway in eukaryotes that can generate ATP, and, for many anaerobic respiring organisms the most important producer of ATP. Therefore, many organisms have evolved fermentation pathways to recycle NAD+ to continue glycolysis to produce ATP for survival. These pathways include ethanol fermentation and lactic acid fermentation.
Sources: en.wikipedia.org
Selenium shows borderline metalloid or nonmetal behaviour. Its most stable form, the grey trigonal allotrope, is sometimes called "metallic" selenium because its electrical conductivity is several orders of magnitude greater than that of the red monoclinic form. The metallic character of selenium is further shown by its lustre, and its crystalline structure, which is thought to include weakly "metallic" interchain bonding. Selenium can be drawn into thin threads when molten and viscous. It shows reluctance to acquire "the high positive oxidation numbers characteristic of nonmetals". It can form cyclic polycations (such as Se2+8) when dissolved in oleums (an attribute it shares with sulfur and tellurium), and a hydrolysed cationic salt in the form of trihydroxoselenium(IV) perchlorate [Se(OH)3]+·ClO–4. The nonmetallic character of selenium is shown by its brittleness and the low electrical conductivity (~10−9 to 10−12 S•cm−1) of its highly purified form. This is comparable to or less than that of bromine (7.95×10–12 S•cm−1), a nonmetal. Selenium has the electronic band structure of a semiconductor and retains its semiconducting properties in liquid form. It has a relatively high electronegativity (2.55 revised Pauling scale). Its reaction chemistry is mainly that of its nonmetallic anionic forms Se2−, SeO2−3 and SeO2−4. Selenium is commonly described as a metalloid in the environmental chemistry literature.
In April 2013, Hird, as coach, was accused of being personally injected with supplements in 2011 and 2012 that would be deemed performance enhancing if he were a player. Essendon players from 2011 and 2012 were also accused of ingesting performance enhancing supplements. As head coach, Hird was subsequently implicated. Following months of rumours and investigations, on 13 August 2013, Hird, along with the Essendon Football Club, senior assistant coach Mark Thompson, football manager Danny Corcoran and club doctor Bruce Reid, was charged by the AFL with bringing the game into disrepute in relation to the poor governance of the supplements program at the club in 2011 and 2012. The club was given 14 days to consider the charges and faced an AFL Commission hearing on 26 August 2013. On 27 August 2013, following much negotiation, Hird accepted charges that he had brought the game into disrepute and abandoned possible Supreme Court action against the AFL and its chief executive, Andrew Demetriou. He maintained that he did little wrong, but said he should have known more about the club's supplements program. He was banned from working at any AFL club in any capacity for twelve months commencing from 25 August 2013. Hird was allowed to attend Essendon matches as a spectator during this period. However, despite not being allowed to pay him for working as a coach during 2014, the club paid Hird $1 million in advance for 2014 in December 2013. A media report on 3 October 2013 said that Hird denied pleading guilty for a reduced charge as alleged by Demetriou.
=== Structure-based === Structure-based drug design (or direct drug design) relies on knowledge of the three dimensional structure of the biological target obtained through methods such as x-ray crystallography or NMR spectroscopy. If an experimental structure of a target is not available, it may be possible to create a homology model of the target based on the experimental structure of a related protein. Using the structure of the biological target, candidate drugs that are predicted to bind with high affinity and selectivity to the target may be designed using interactive graphics and the intuition of a medicinal chemist. Alternatively, various automated computational procedures may be used to suggest new drug candidates. Current methods for structure-based drug design can be divided roughly into three main categories. The first method is identification of new ligands for a given receptor by searching large databases of 3D structures of small molecules to find those fitting the binding pocket of the receptor using fast approximate docking programs. This method is known as virtual screening. A second category is de novo design of new ligands. In this method, ligand molecules are built up within the constraints of the binding pocket by assembling small pieces in a stepwise manner. These pieces can be either individual atoms or molecular fragments. The key advantage of such a method is that novel structures, not contained in any database, can be suggested. A third method is the optimization of known ligands by evaluating proposed analogs within the binding cavity.
=== Ribosome-mediated attenuation === In this situation RNA polymerase is dependent on (lagging) ribosome activity; if the ribosome pauses due to insufficient charged tRNA then the anti-terminator structure is favoured. The canonical attenuator example of the trp operon uses this mechanism in E. coli. Similar regulatory mechanisms have been found in many amino acid biosynthetic operons.
== Early life == Gemma Clair Collins was born on 31 January 1981 at Oldchurch Hospital in Romford, East London. She is the daughter of Joan Collins (née Williams; 21 February 1955 — 29 July 2026), who worked as a part-time hairdresser, and Alan Collins, the director of Unisystems Freight, an import-export shipping company. She has an older brother named Russell, who is also a director of their father's company. Shortly after her birth, the family moved from a house in Collier Row and Collins was raised in Rise Park where she attended Rise Park Infant School. Collins described her childhood as being "filled with love" and said that although money was "tight", her father still managed to take them on family holidays and said she has "very happy memories" of her early years. Collins then went on to attend Frances Bardsley Academy for Girls. She enjoyed performing arts from a young age and attended dance lessons and stage school. At the age of 14, she began attending the Sylvia Young Theatre School and successfully auditioned for a part in The Sound of Music. Collins' mother was encouraging and said she knew that her daughter would one day become famous. Collins was bullied at school for being outgoing and confident, and so following the success of her father's business, her parents decided to move her to Raphael Independent School, a private school, for her final year of education. She left school at the age of 16 with a G in GCSE Maths.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.